Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Cooper, Curtis ^a   Thorne, Anona ^b   Klein, Marina ^c   Conway, Brian ^d   Boivin, Guy ^e   Haase, David ^f   Shafran, Stephen ^g   Zubyk, Wendy ^b   Singer, Joel ^b   Halperin, Scott ^f   Walmsley, Sharon ^h  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Canadian HIV Trials Network   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

^f DALHOUSIE UNIVERSITY   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; FLUVIRAL; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS RNA; VIRUS ANTIGEN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; FEMALE; HEMAGGLUTINATION INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; ANTIGENS, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA VACCINES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 79953049123     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017758     Document Type: Article

References (29)

1. Beck JM, Rosen MJ, Peavy HH, (2001) Pulmonary complications of HIV infection. 4th NHLBI Workshop: Am J Respir Crit Care Med pp. 2120-2126.
2. Malaspina A, Moir S, Orsega SM, Vasquez J, Miller NJ, et al. (2005) Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis 191: 1442-1450.
3. Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E, (2002) Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 20 (Suppl 5): B29-32.
4. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, et al. (1999) Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 29: 1306-1310.
5. Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, et al. (2005) CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 19: 1473-1479.
6. Beck JM, Rosen MJ, Peavy HH, (2001) Pulmonary complications of HIV infection. Report of the Fourth NHLBI Workshop. Am J Respir Crit Care Med 164: 2120-2126.
7. Fine AD, Bridges CB, De Guzman AM, Glover L, Zeller B, et al. (2001) Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis 32: 1784-1791.
8. Radwan HM, Cheeseman SH, Lai KK, Ellison IR, (2000) Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis 31: 604-606.
9. Safrin S, Rush JD, Mills J, (1990) Influenza in patients with human immunodeficiency virus infection. Chest 98: 33-37.
10. Lin JC, Nichol KL, (2001) Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 161: 441-446.
11. Neuzil KM, Reed GW, Mitchel EF Jr, Griffin MR, (1999) Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 281: 901-907.
12. Ragni MV, Ruben FL, Winkelstein A, Spero JA, Bontempo FA, et al. (1987) Antibody responses to immunization of patients with hemophilia with and without evidence of human immunodeficiency virus (human T-lymphotropic virus type III) infection. J Lab Clin Med 109: 545-549.
13. Redfield RR, Wright DC, James WD, Jones TS, Brown C, et al. (1987) Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 316: 673-676.
14. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R, (2000) Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 18: 3040-3049.
15. Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, et al. (1995) Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 182: 1727-1737.
16. Chadwick EG, Chang G, Decker MD, Yogev R, Dimichele D, et al. (1994) Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J 13: 206-211.
17. Huang KL, Ruben FL, Rinaldo CR Jr, Kingsley L, Lyter DW, et al. (1987) Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. JAMA 257: 2047-2050.
18. Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, et al. (1989) The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 262: 779-783.
19. Klein MB, Lu Y, DelBalso L, Cote S, Boivin G, (2007) Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis 45: 234-240.
20. Nichol KL, (1996) Booster doses of influenza vaccine. JAMA 276: 1857.
21. (2002) WHO Manual on Animal Influenza Diagnosis and Surveillance. Geneva, Switzerland World Health Organization.
22. Boivin G, De Serres G, Cote S, Gilca R, Abed Y, et al. (2003) Human metapneumovirus infections in hospitalized children. Emerg Infect Dis 9: 634-640.
23. CPMP (1997) Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. Unit TEAftEoMP-HME, eds. CPMP/BWP/214/96 London, UK The European Agency for the Evaluation of Medicinal Products.
24. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, et al. (2006) Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55: 1-42.
25. Iorio AM, Alatri A, Francisci D, Preziosi R, Neri M, et al. (1997) Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and-seronegative ex-intravenous drug users. Vaccine 15: 97-102.
26. Anema A, Mills E, Montaner J, Brownstein JS, Cooper C, (2008) Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med 9: 57-61.
27. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, et al. (2009) Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 361: 2405-2413.
28. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, et al. (2009) Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 361: 2424-2435.
29. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW, (2008) CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 46: 1310-1314.